Celldex Therapeutics (CLDX) Non-Current Assets (2010 - 2026)

Celldex Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $52.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 13.82% year-over-year to $52.0 million; the TTM figure through Mar 2026 stood at $188.5 million (up 11.61% YoY), while the FY2025 annual figure was $48.3 million, up 6.95% from the prior year.
• Non-Current Assets was $52.0 million for Q1 2026 at Celldex Therapeutics, up from $48.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $52.0 million in Q1 2026 to a low of $33.3 million in Q1 2022.
• Historically, Non-Current Assets has averaged $39.2 million across 5 years, with a median of $35.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets decreased 11.24% in 2022, then surged 36.37% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $35.0 million in 2022, then dropped by 3.16% to $33.9 million in 2023, then jumped by 33.14% to $45.2 million in 2024, then climbed by 6.95% to $48.3 million in 2025, then advanced by 7.68% to $52.0 million in 2026.
• The last three Non-Current Assets figures came in at $52.0 million (Q1 2026), $48.3 million (Q4 2025), and $44.1 million (Q3 2025), per Business Quant data.